Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Marek

Showing results (121-130 of 144) with videos related to

Pageof 15
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|March 25, 2018
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative CohortTanya Simuni, Andrew Siderowf, Shirley Lasch, et al.
The Lancet. Neurology|November 4, 2019
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional studyTanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, et al.
Annals of Neurology|July 11, 2025
Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior DisorderDaniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 17, 2020
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease ProgressionBrit Mollenhauer, Mohammed Dakna, Niels Kruse, et al.
Clinical Pharmacology and Therapeutics|April 24, 2021
A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 MutationMalidi Ahamadi, Nitin Mehrotra, Nathan Hanan, et al.
Annals of Clinical and Translational Neurology|December 20, 2018
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohortKenneth Marek, Sohini Chowdhury, Andrew Siderowf, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 20, 2020
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional StudyTanya Simuni, Michael C Brumm, Liz Uribe, et al.
Annals of Neurology|May 11, 2026
Recruitment Strategies across the Spectrum of Neuronal Synuclein DiseaseAndrew Siderowf, Laura E A Heathers, Kimberly Fabrizio, et al.
Neurology|February 2, 2024
Evaluation of ATN<sub>PD</sub> Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson DiseaseKatheryn A Q Cousins, David J Irwin, Thomas F Tropea, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 27, 2018
Movement disorder society criteria for clinically established early Parkinson's diseaseDaniela Berg, Charles H Adler, Bastiaan R Bloem, et al.
Pageof 15

Showing results (121-130 of 144) with videos related to

Sort By:
Pageof 15
Movement Disorders : Official Journal of the Movement Disorder Society|March 25, 2018
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative CohortTanya Simuni, Andrew Siderowf, Shirley Lasch, et al.
The Lancet. Neurology|November 4, 2019
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional studyTanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, et al.
Annals of Neurology|July 11, 2025
Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior DisorderDaniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 17, 2020
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease ProgressionBrit Mollenhauer, Mohammed Dakna, Niels Kruse, et al.
Clinical Pharmacology and Therapeutics|April 24, 2021
A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 MutationMalidi Ahamadi, Nitin Mehrotra, Nathan Hanan, et al.
Annals of Clinical and Translational Neurology|December 20, 2018
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohortKenneth Marek, Sohini Chowdhury, Andrew Siderowf, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 20, 2020
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional StudyTanya Simuni, Michael C Brumm, Liz Uribe, et al.
Annals of Neurology|May 11, 2026
Recruitment Strategies across the Spectrum of Neuronal Synuclein DiseaseAndrew Siderowf, Laura E A Heathers, Kimberly Fabrizio, et al.
Neurology|February 2, 2024
Evaluation of ATN<sub>PD</sub> Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson DiseaseKatheryn A Q Cousins, David J Irwin, Thomas F Tropea, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 27, 2018
Movement disorder society criteria for clinically established early Parkinson's diseaseDaniela Berg, Charles H Adler, Bastiaan R Bloem, et al.
Pageof 15